submit url • add directory • radiology jobs ♦ radiologist jobs ♦ Psychiatry job ♦ Emergency Medicine job
Today's News:
Annals of Hematology (Online First™)
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine
Sun, 13 May 2012 05:59:51 -0000
Abstract Ribosomal protein (RP) L23 has been suggested to be a negative regulator of cell apoptosis. In the present study, we analyzed RPL23 expression in 169 patients with myelodysplastic syndrome (MDS) by using real-time PCR. The apoptosis of CD34+ marrow cells was examined by flow cytometry, and the correlation between RPL23 expression levels and apoptosis in CD34+ cells was assessed. We then analyzed the clinical significance of RPL23 expression for predicting disease progression and patient survival as well as therapeutic response in patients administered with a cytarabine, homoharringtonine, and G-CSF (CHG) regimen or decitabine therapy. Increased RPL23 expression was found in patients with higher-risk MDS than in patients with lower-risk disease (p = 0.004). RPL23 expression levels were found being inversely correlated with decreased apoptotic ratio of CD34+ cells in higher-risk patients (r = −0.672, p < 0.001). Compared to patients with normal RPL23 expression levels, those with increased RPL23 expression presented higher rates of transformation to acute myeloid leukemia (p = 0.005) and reduced 2-year survival rates (p = 0.012). Multivariate regression analysis showed that RPL23 expression level was an independent predictor of prognosis, regardless of patient age, IPSS score, or hemoglobin level. Moreover, patients with RPL23 over-expression appeared to have lower response rates to CHG chemotherapy (p = 0.027) but similar response rates to decitabine treatment. In conclusion, the over-expression of RPL23 might confer apoptosis resistance in CD34+ cells, which may lead to disease progression and adverse prognosis in MDS. Increased RPL23 expression was an inverse indicator for CHG regimen, but not for decitabine treatment. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00277-012-1486-2Authors Lingyun Wu, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaXiao Li, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaFeng Xu, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaChunkang Chang, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaQi He, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaZheng Zhang, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaYan Zhang, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 China Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS)
Fri, 11 May 2012 06:01:14 -0000
Abstract The prognosis of acute myelogenous leukemia (AML) in the elderly patients is extremely poor. Although several previous studies have suggested that intensive chemotherapy is associated with a better prognosis, there may have been a selection bias. Therefore, we retrospectively evaluated the impact of intensive chemotherapy for AML in the elderly by stratifying patients according to a propensity score. Eighty-one AML patients aged 70 years or more were included in this study. Patients with acute promyelocytic leukemia were not included. A propensity score for the use of intensive chemotherapy was calculated from four factors at diagnosis. Forty-five patients received intensive chemotherapy, whereas 36 received low-dose or no chemotherapy. We stratified the patients into quartiles based on the propensity score. The numbers of patients in the first, second, third, and forth quartiles who received intensive chemotherapy were 5 of 21, 10 of 20, 12 of 20, and 18 of 20, respectively. A stratified log-rank test showed significantly better overall survival in the intensive chemotherapy group (P = 0.0088). Especially, in the combined second and third quartiles, which showed an equal tendency for intensive and non-intensive strategies; overall survival at 3 years was 37.5 % for the intensive chemotherapy group and 13.0 % for the non-intensive chemotherapy group (P = 0.0022). A conventional multivariate analysis confirmed that intensive chemotherapy was beneficial (hazard ratio 0.50, 95 % confidence interval 0.27–0.93, P = 0.028). In conclusion, intensive chemotherapy may prolong overall survival in elderly AML patients who are considered to be able to tolerate such treatment based on factors at diagnosis. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00277-012-1487-1Authors Kumi Oshima, Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, JapanWataru Takahashi, Department of Hematology, Dokkyo University School of Medicine, Tochigi, JapanYuki Asano-Mori, Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, JapanKoji Izutsu, Division of Hematology, NTT Kanto Medical Center, Tokyo, JapanTsuyoshi Takahashi, Department of Hematology and Oncology, University of Tokyo Hospital, Tokyo, JapanYukihiro Arai, Department of Hematology, Dokkyo University School of Medicine, Tochigi, JapanYasunori Nakagawa, Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, JapanKensuke Usuki, Division of Hematology, NTT Kanto Medical Center, Tokyo, JapanMineo Kurokawa, Department of Hematology and Oncology, University of Tokyo Hospital, Tokyo, JapanKenshi Suzuki, Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, JapanKinuko Mitani, Department of Hematology, Dokkyo University School of Medicine, Tochigi, JapanYoshinobu Kanda, Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Hereditary protein C deficiency in Indian patients with venous thrombosis
Fri, 11 May 2012 06:01:13 -0000
Abstract Approximately, 4–11 % of the patients with idiopathic venous thrombosis (VT) show protein C (PC) deficiency. The molecular pathology of PC deficiency was analyzed in 102 patients; 98 healthy controls were also studied to assess the association of various polymorphisms with reduced PC levels. PROC gene mutations were detected only in 8 (7.8 %) patients with reduced PC levels. PROC promoter region CG polymorphisms showed statistically significant association with reduced PC levels (p < 0.001). PC deficiency in Indian VT patients can, thus, largely be explained by PROC gene promoter CG polymorphisms; only a small fraction of the patients show specific mutations in PROC gene. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00277-012-1483-5Authors Navin Pai, National Institute of Immunohaematology (ICMR), 13th Floor, New MS Building, KEM Hospital Campus, Parel, Mumbai, 400012 IndiaKanjaksha Ghosh, National Institute of Immunohaematology (ICMR), 13th Floor, New MS Building, KEM Hospital Campus, Parel, Mumbai, 400012 IndiaShrimati Shetty, National Institute of Immunohaematology (ICMR), 13th Floor, New MS Building, KEM Hospital Campus, Parel, Mumbai, 400012 India Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Permanent Hematology-Oncology Jobs
Hematology-Oncology jobs
Thu, 17 May 2012 02:49:21 -0500
All Hematology-Oncology jobs for Thu May 17 2012
Hematology-Oncology jobs in "Private Practice Oncology Group in North Carolina Looking for a Physician" - NC
Wed, 16 May 2012 12:15:44 -0600
Job 94501 Private Practice Oncology Group in North Carolina Looking for a Physician Join 2 Oncologists 1:3 call Existing patient base Chemo done in office Admit to 2 hospitals Competitive salary to start
Hematology-Oncology jobs in "Marvelous Oncology Opportunity - Cancer Center in Southern California" - CA
Wed, 16 May 2012 12:15:44 -0600
Job 94545 Terrific cancer center in the Los Angeles area seeks to add an Oncologist to their growing practice. The center has everything needed to treat cancer patients including radiation oncology, radiology
Subscribe to Hematology RSS feed 
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine
Sun, 13 May 2012 05:59:51 -0000
Abstract Ribosomal protein (RP) L23 has been suggested to be a negative regulator of cell apoptosis. In the present study, we analyzed RPL23 expression in 169 patients with myelodysplastic syndrome (MDS) by using real-time PCR. The apoptosis of CD34+ marrow cells was examined by flow cytometry, and the correlation between RPL23 expression levels and apoptosis in CD34+ cells was assessed. We then analyzed the clinical significance of RPL23 expression for predicting disease progression and patient survival as well as therapeutic response in patients administered with a cytarabine, homoharringtonine, and G-CSF (CHG) regimen or decitabine therapy. Increased RPL23 expression was found in patients with higher-risk MDS than in patients with lower-risk disease (p = 0.004). RPL23 expression levels were found being inversely correlated with decreased apoptotic ratio of CD34+ cells in higher-risk patients (r = −0.672, p < 0.001). Compared to patients with normal RPL23 expression levels, those with increased RPL23 expression presented higher rates of transformation to acute myeloid leukemia (p = 0.005) and reduced 2-year survival rates (p = 0.012). Multivariate regression analysis showed that RPL23 expression level was an independent predictor of prognosis, regardless of patient age, IPSS score, or hemoglobin level. Moreover, patients with RPL23 over-expression appeared to have lower response rates to CHG chemotherapy (p = 0.027) but similar response rates to decitabine treatment. In conclusion, the over-expression of RPL23 might confer apoptosis resistance in CD34+ cells, which may lead to disease progression and adverse prognosis in MDS. Increased RPL23 expression was an inverse indicator for CHG regimen, but not for decitabine treatment. Content Type Journal ArticleCategory Original ArticlePages 1-8DOI 10.1007/s00277-012-1486-2Authors Lingyun Wu, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaXiao Li, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaFeng Xu, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaChunkang Chang, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaQi He, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaZheng Zhang, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 ChinaYan Zhang, Hematology Division, Sixth Hospital Affiliated to Shanghai Jiaotong University, Shanghai, 200233 China Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS)
Fri, 11 May 2012 06:01:14 -0000
Abstract The prognosis of acute myelogenous leukemia (AML) in the elderly patients is extremely poor. Although several previous studies have suggested that intensive chemotherapy is associated with a better prognosis, there may have been a selection bias. Therefore, we retrospectively evaluated the impact of intensive chemotherapy for AML in the elderly by stratifying patients according to a propensity score. Eighty-one AML patients aged 70 years or more were included in this study. Patients with acute promyelocytic leukemia were not included. A propensity score for the use of intensive chemotherapy was calculated from four factors at diagnosis. Forty-five patients received intensive chemotherapy, whereas 36 received low-dose or no chemotherapy. We stratified the patients into quartiles based on the propensity score. The numbers of patients in the first, second, third, and forth quartiles who received intensive chemotherapy were 5 of 21, 10 of 20, 12 of 20, and 18 of 20, respectively. A stratified log-rank test showed significantly better overall survival in the intensive chemotherapy group (P = 0.0088). Especially, in the combined second and third quartiles, which showed an equal tendency for intensive and non-intensive strategies; overall survival at 3 years was 37.5 % for the intensive chemotherapy group and 13.0 % for the non-intensive chemotherapy group (P = 0.0022). A conventional multivariate analysis confirmed that intensive chemotherapy was beneficial (hazard ratio 0.50, 95 % confidence interval 0.27–0.93, P = 0.028). In conclusion, intensive chemotherapy may prolong overall survival in elderly AML patients who are considered to be able to tolerate such treatment based on factors at diagnosis. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00277-012-1487-1Authors Kumi Oshima, Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, JapanWataru Takahashi, Department of Hematology, Dokkyo University School of Medicine, Tochigi, JapanYuki Asano-Mori, Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, JapanKoji Izutsu, Division of Hematology, NTT Kanto Medical Center, Tokyo, JapanTsuyoshi Takahashi, Department of Hematology and Oncology, University of Tokyo Hospital, Tokyo, JapanYukihiro Arai, Department of Hematology, Dokkyo University School of Medicine, Tochigi, JapanYasunori Nakagawa, Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, JapanKensuke Usuki, Division of Hematology, NTT Kanto Medical Center, Tokyo, JapanMineo Kurokawa, Department of Hematology and Oncology, University of Tokyo Hospital, Tokyo, JapanKenshi Suzuki, Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, JapanKinuko Mitani, Department of Hematology, Dokkyo University School of Medicine, Tochigi, JapanYoshinobu Kanda, Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Hereditary protein C deficiency in Indian patients with venous thrombosis
Fri, 11 May 2012 06:01:13 -0000
Abstract Approximately, 4–11 % of the patients with idiopathic venous thrombosis (VT) show protein C (PC) deficiency. The molecular pathology of PC deficiency was analyzed in 102 patients; 98 healthy controls were also studied to assess the association of various polymorphisms with reduced PC levels. PROC gene mutations were detected only in 8 (7.8 %) patients with reduced PC levels. PROC promoter region CG polymorphisms showed statistically significant association with reduced PC levels (p < 0.001). PC deficiency in Indian VT patients can, thus, largely be explained by PROC gene promoter CG polymorphisms; only a small fraction of the patients show specific mutations in PROC gene. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00277-012-1483-5Authors Navin Pai, National Institute of Immunohaematology (ICMR), 13th Floor, New MS Building, KEM Hospital Campus, Parel, Mumbai, 400012 IndiaKanjaksha Ghosh, National Institute of Immunohaematology (ICMR), 13th Floor, New MS Building, KEM Hospital Campus, Parel, Mumbai, 400012 IndiaShrimati Shetty, National Institute of Immunohaematology (ICMR), 13th Floor, New MS Building, KEM Hospital Campus, Parel, Mumbai, 400012 India Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Permanent Hematology-Oncology Jobs
Hematology-Oncology jobs
Thu, 17 May 2012 02:49:21 -0500
All Hematology-Oncology jobs for Thu May 17 2012
Hematology-Oncology jobs in "Private Practice Oncology Group in North Carolina Looking for a Physician" - NC
Wed, 16 May 2012 12:15:44 -0600
Job 94501 Private Practice Oncology Group in North Carolina Looking for a Physician Join 2 Oncologists 1:3 call Existing patient base Chemo done in office Admit to 2 hospitals Competitive salary to start
Hematology-Oncology jobs in "Marvelous Oncology Opportunity - Cancer Center in Southern California" - CA
Wed, 16 May 2012 12:15:44 -0600
Job 94545 Terrific cancer center in the Los Angeles area seeks to add an Oncologist to their growing practice. The center has everything needed to treat cancer patients including radiation oncology, radiology
Sites:
BloodLine: BloodLine is dedicated to furthering and enhancing the fields of hematology and oncology through the presentation of knowledge in the following manners: the publication of original clinical and laboratory research; the creation of comprehensive reference works that are continuously useful to...Atlas of hematology: The Atlas of Haematology contains about 700 illustrations of blood and bone marrow cells
Atlas of Hematology: CDROM Atlas of hematology with 1500 color images, by Prof. John Meletis. Range of examples available online.
Atlas of Hematology: Contains images of blood cells with descriptions.
Aurea R. Tomeski, M.D.: Dr. Tomeski - Internal Medicine - Hematology - Oncology
BloodMed: BloodMed.com - The global source for hematology education, practice and research
European Federation for Immunogenetics: Website for the European Federation of Immunogenetics.
Factor Replacement by Continuous Infusion: Guide for health professionals who provide continuous infusion clotting factor replacement therapy to individuals with bleeding disorders. Describes theory behind how to prescribe, administer, and monitor replacement therapy.
Family Practice Notebook: Hematology and Oncology: Find chapters about Anemia, Cancer, Coagulopathy, Examination, Hemoglobin, Hemolysis, Histiocytosis, Leukemia, Lymph, Marrow, Platelet, Procedure, Sarcoma, Symptom Evaluation and Vascular. Related chapters from other specialties include Cardiovascular, Dermatology, Endocrinology, Otolaryngology,...
General Practice Notebook - Haematology: Coverage of this medical speciality.
Haem.net: Haem.net - The Web Journal of Laboratory Haematology to serve the educational needs of anyone with an interest in Laboratory Haematology in the U.K. and overseas
Haematological Malignancy Diagnostic Service: The diagnosis of leukaemia, lymphoma, myeloma and related blood disorders by cellular and molecular investigation. Contents include the current classification of the myeloproliferative and lymphoproliferative disorders, morphology and cytochemistry, and diagnostic procedures including antibody ba...
Haematology: Haematology & Pathology Education Website for medical laboratory officer`s student or a clinical haematologist in training. Contains an Interactice questions and answers style haematology atlas set of slides. its an online hematology book. particularly useful for hematologists and pathologist...
Hematology: Wikipedia article describing branch of medicine, related diseases, tests, and treatments.
Hematology and Oncology Associates Of Virginia: Virginia Cancer Institute is dedicated to the highest quality medical care for the treatment of diseases of the blood (hematology) to the long-term management of cancer for our patients .
Hematology jobs: Hematology jobs at Physician Employment with automatic email updates.
Hematology, by Ellen C. Ebert, MD: Grant-funded research report which requires the Adobe Acrobat Reader to view.
Hematopathology Correlative Pathology Course: From the UAB Department of Pathology, Birmingham, Alabama.
Machaon Diagnostics: Clinical reference laboratory developing products for diagnosis and monitoring of hemostatic and thrombotic conditions.
Ortho-WIRE: Educational resource for transfusion medicine applications in immuno-hematology, blood group serology, and hemolytic disease of the newborn.
The Vanderbilt Hemostasis-Thrombosis Clinic: The Vanderbilt Hemostasis-Thrombosis Clinic provides comprehensive care for inherited disorders of bleeding or coagulation. Committed to patient care, education, and clinical research, we have over 75 years of experience caring for people with hemophilia, thrombophilia, and other blood disorders.
This directory is based on the Open Directory and may have been modified